Drug Discovery AI Talk

Three fresh stories, one question: what happens when AI stops being a chatbot and starts doing the work of a lab? A swarm of AI agents reads millions of brain cells in minutes and surfaces a new hypothesis for neurodegeneration. A robotics startup bets that machines can learn a chemist's hands. And a pharma giant gives its scientists an AI research partner. We walk through what each story actually shows — and the long road from a half-hour hypothesis to a drug. Produced by Dr. Jake Chen.

Three fresh stories, one question: what happens when AI stops needing a protein's 3D shape and starts working with biology as it actually behaves? A virtual cell trained on proteins rather than genes predicts how cancer cells respond to drugs hour by hour. A new structure-free model finds drug binding sites on disordered proteins that no structure-based method can touch. And the first drug with both an AI-identified target and an AI-designed molecule has dosed its first Phase III patient. We walk through what each result actually shows, and what it doesn't. Produced by Dr. Jake Chen.

AI can now generate millions of molecules, thousands of drug targets, and entire scientific manuscripts in hours — but our capacity to validate any of it hasn't kept pace. This episode walks through the trust crisis in AI drug discovery: from ultra-large virtual screening libraries to AI-generated papers arriving faster than peer review can handle, from citation errors in machine-written manuscripts to the clinical programs that give real reason for optimism. The central question is no longer whether AI can generate drug candidates, but whether it can reliably improve therapeutic decisions — and why trustworthy evidence must become the industry's most valuable asset. Produced by Dr. Jake Chen.

Biohub's Virtual Biology Initiative just expanded to $1.8 billion — backed by the DOE, NIH, Google DeepMind, Isomorphic Labs, and Meta — to build the data foundations for predictive AI in biology. But a new perspective argues the field is celebrating too early: today's biological data are sparse across the spatial, temporal, and causal dimensions that actually determine how cells respond to drugs. This episode walks through why virtual cells are not digital twins, where the models could genuinely accelerate drug discovery first, and the validation ladder that separates credible prediction from hype. Produced by Dr. Jake Chen.

On September 10, 2026, Insilico Medicine dosed the first patient in the Phase III GENESIS-IPF-3 trial of rentosertib (ISM001-055) for idiopathic pulmonary fibrosis - the first drug with both an AI-discovered target and an AI-designed molecule to reach Phase III. We break down the TNIK story, the Phase IIa data published in Nature Medicine, the provocative aging-clock signals in Nature Biotechnology, and what this milestone really proves - and doesn't - about AI drug discovery. Produced by Dr. Jake Chen.